Bristol-Myers Strikes $5M Deal For Orencia

Law360, New York (April 8, 2008, 12:00 AM EDT) -- Bristol-Myers Squibb Co. has agreed to pay $5 million plus royalties to settle a patent dispute with Repligen Corp. over the sale of rheumatoid arthritis drug Orencia, Repligen said Tuesday.

Under the agreement, Repligen and its co-plaintiff, the University of Michigan, will grant Bristol-Myers an exclusive license to U.S. Patent No. 6,685,941, which has been at the center of a dispute between the parties in the U.S. District Court for the Eastern District of Texas.

In addition to the initial $5 million payment, New York-based Bristol-Myers...
To view the full article, register now.